NCT01553136已完成2 期
1/2-Multi-site Study: Varenicline Treatment of Alcohol Dependent Smokers
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 131
- 试验地点
- 2
- 主要终点
- Percentage of Heavy Drinking Days During the Last 8 Weeks of Treatment
研究概览
简要总结
The purpose of this study is to determine whether varenicline is effective in the treatment of alcohol dependence in smokers.
详细描述
Building upon knowledge about the role of nicotinic acetylcholine receptors in alcohol drinking and smoking, varenicline, a smoking cessation treatment that targets these receptors, will be tested as a potential treatment for alcohol dependent smokers seeking alcohol treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •are 18 - 70 years of age and seeking treatment of alcohol drinking;
- •meet DSM-IV TR Criteria for Alcohol Dependence
- •report smoking 100 cigarettes or more in their lifetime and currently smoke at least twice weekly on average in the past 90 days and have a urinary cotinine level of > 30ng/mL by semi-quantitative urinalysis or equivalent plasma cotinine level (> 6 ng/mL);
- •report heavy drinking on at least 2 days on average per week (i.e., ≥ 4 drinks on an occasion for women and ≥ 5 drinks for men) for the past 90 days and no more than 7 consecutive days of abstinence at intake.
排除标准
- •exhibit current, clinically significant physical disease or abnormality based on medical history, physical examination, or routine laboratory evaluation including:
- •any unexplained elevations in liver enzymes (i.e., transaminases, bilirubin)
- •clinically significant, unstable cardiovascular disease/uncontrolled hypertension
- •hepatic or renal impairment
- •severe obstructive pulmonary disease
- •diabetes mellitus requiring insulin or certain oral medications (i.e., sulfonylureas) and an A1C hemoglobin test score of > 7 for participants not prescribed these medications
- •baseline systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 95 mm Hg
- •have a history of cancer (except treated basal cell or squamous cell carcinoma of the skin)
- •have a history of serious hypersensitivity reactions or skin reactions to varenicline;
- •exhibit serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe major depression, panic disorder, borderline personality disorder, organic mood or mental disorders by history or psychological examination
- •report current suicidal ideation (past 6 months) or lifetime hx of suicidal behavior assessed with the Columbia Suicide Severity Rating Scale 60; or risk for aggression using a cut-off of 15 or more on the Overt Aggression Scale - Modified Aggression Scale or 6 or more on the OAS-M Irritability Subscale
- •have used any psychotropic drug in the past month, except individuals who are on a stable dose of a Selective Serotonin Reuptake Inhibitor for at least two months or who report occasional use of prescription sleep aids that they are willing to discontinue;
- •have a current DSM-IV diagnosis of drug dependence other than nicotine or alcohol
- •are at risk for an alcohol withdrawal syndrome as evidenced by:
- •a history of seizures, delirium, or hallucinations during alcohol withdrawal
- •a Clinical Institute Withdrawal Assessment scale 62 score of > 8,
- •report drinking to avoid withdrawal symptoms
- •have required medical treatment of alcohol withdrawal within the past 6 months
- •have used another investigational drug within 30 days or have used medications to treat alcohol (e.g., naltrexone, topiramate, acamprosate, disulfiram) or nicotine use (e.g., clonidine, varenicline, bupropion, nicotine replacement) in the past 3 months or intend to use these medications;prior use of nicotine replacement in situations where smoking is not permitted (e.g., planes) without the intention to quit smoking is not exclusionary;
- •intend to donate blood or blood products during the treatment phase of the study
- •have a Body Mass Index (calculated as weight in kilograms divided by the square of height in meters) less than 15 or greater than 39.99 or weight less than 45 kg;
- •are a female of childbearing potential who is pregnant, nursing, or not practicing effective contraception (oral, injectable, or implantable contraceptives, intrauterine device, or barrier method with spermicide).
研究组 & 干预措施
Sugar pill
Placebo Comparator
干预措施: Varenicline (Drug)
Varenicline
Active Comparator
干预措施: Varenicline (Drug)
结局指标
主要结局
Percentage of Heavy Drinking Days During the Last 8 Weeks of Treatment
时间窗: 8 weeks
The percentage of days of heavy drinking will be examined over the final 8 weeks of the study. A heavy drinking day is defined as 5 or more standard drinks for men and 4 or more standard drinks for women. A standard drink contains approximately 0.6 fluid ounces of pure alcohol. Presented here is the average of the 8 weeks (reported as week 17 originally).
次要结局
- Smoking Abstinence(Weeks 13-16)
- Drinking Related Consequences(End of treatment (Week 17))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Human Laboratory Study of Varenicline for Alcohol Use DisorderAlcohol Use DisorderNCT03035708National Institute on Alcohol Abuse and Alcoholism (NIAAA)47
已完成
2 期
Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?Alcohol DependenceNCT00846859Sahlgrenska University Hospital, Sweden162
已完成
4 期
Varenicline Treatment in Alcohol and Nicotine Dependent Patients With SchizophreniaNicotine DependenceSchizophreniaSchizoaffective DisorderAlcohol DependenceNCT00727103State University of New York - Upstate Medical University10
Unknown
2 期
Varenicline for Alcohol DependenceAlcohol DependenceNCT01071187Johannes Gutenberg University Mainz40
已完成
3 期
The Effects of Varenicline on Cognitive Function in Patients With SchizophreniaSchizophreniaNCT00523445Inje University120